# Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

> **NCT00003693** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Dolastatin 10

## Key facts

- **NCT ID:** NCT00003693
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-12-18
- **Primary completion:** 2001-10-30
- **Final completion:** 2001-10-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003693, "Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00003693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*